🔥🔥🔥 #ESMO26 DeLLphi-305 in @NEJM

Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC (n=563)

➡️ mOS 21.1 vs 12.7 mo | HR 0.42
➡️ mPFS 7.4 vs 1.9 mo | HR 0.34
➡️ ORR 26% vs 4% | CR 0.9% | mDoR 12.7 mo
➡️ G≥3 AEs 47% vs 41% | CRS in ~50%, mostly G1-2, manageable

🔍 OS here is a game changer. New 1L maintenance standard, ahead of lurbi-atezo.

🙋CRs almost absent and DoR ~1 year. Still far from the long-term tail we see with PD-1 blockade in other tumour types. We can’t cure without CRs

@myESMO @_SEOM @OncoAlert @Larvol

#LCSM #SCLC